Wellington Management Group LLP acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 40,959 shares of the biotechnology company's stock, valued at approximately $565,000. Wellington Management Group LLP owned about 0.09% of Capricor Therapeutics at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its stake in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in Capricor Therapeutics during the 4th quarter worth $68,000. AlphaQuest LLC bought a new stake in Capricor Therapeutics during the 4th quarter worth $78,000. Finally, New York State Common Retirement Fund increased its holdings in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Price Performance
Capricor Therapeutics stock opened at $14.23 on Friday. The stock's 50 day moving average is $10.32 and its 200 day moving average is $12.92. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The firm has a market cap of $649.98 million, a P/E ratio of -13.42 and a beta of 0.84.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. During the same quarter last year, the firm posted ($0.31) EPS. Equities analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.
Analyst Ratings Changes
CAPR has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Roth Capital began coverage on shares of Capricor Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price on the stock. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $35.50.
Check Out Our Latest Research Report on CAPR
Capricor Therapeutics Company Profile
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
